The galectin-3 Inhibitors project tests a small molecule under development for peripheral indications for treating neuroinflammation in an Alzheimer’s mouse model. By blocking galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. Galectin-3 is involved in neuroinflammation, thereby the inhibitor has a potential to be used in multiple neurodegenerative diseases.

Relieva is redefining therapeutic innovation through the world’s first proprietary cannabis and hemp pre-roll blend engineered for targeted pain relief. Leveraging advanced cannabinoid and terpene research, Relieva integrates scientific precision, sustainable production, and blockchain-enabled IP tokenization to establish a new benchmark in functional medicine innovation and therapeutic transparency.

We are developing a new gene therapy to help our canine companions stay stronger, move more comfortably, and enjoy healthier lives as they age. By supporting muscle growth, easing pain, and calming inflammation linked to arthritis, our follistatin therapy aims to improve everyday mobility and overall wellbeing.

Our Moon Drops for Skin Longevity serum optimizes the clinically proven Ferulic Acid + Vitamin C + Vitamin E winning combo using safe, high-purity actives. The combination of our Sun Drops UV filter enhances anti-aging skin protection and restoration with active development powered by inclusive decentralized trial protocols.

We are developing a new RNA-based treatment to target a key longevity gene, aiming to stop the tissue damage behind chronic back pain and offer a safer, longer-lasting solution.

Nootropics DAO is building the world's most effective global infrastructure for decentralized research, discovery, and commercialization of powerful solutions for human cognitive enhancement. By creating an open-science ecosystem that aligns professional researchers, citizen-scientists, and biohackers to govern a community-directed research and development pipeline with hyper-efficient feedback loops, Nootropics DAO is operating to become the dominant force in the rapidly growing nootropics industry.

FatDAO addresses the global obesity crisis, aiming to advance research and solutions for weight management and metabolic health. With 2.2 billion overweight or obese adults worldwide, obesity and related diseases like diabetes and cardiovascular conditions severely impact public health and quality of life. Our vision is to become the “on-chain Eli Lilly,” driving breakthroughs in obesity treatment and reshaping the future of metabolic health.

Accelerating a cure for 100M Long COVID patients. By incentivizing scientists, patients and supporters to collaborate and share data, we’re creating an open marketplace for rapid R&D and commercialization of new treatments for Long COVID. Our first treatment launches January 2025.

Empowering the future of mycology by creating a global, community-driven platform that funds and accelerates fungal research, innovation, and environmental solutions.

Revolutionizing spine care for millions worldwide. By leveraging blockchain, AI, and collaborative decentralized science, SpineDAO creates an open platform for optimizing surgical decisions, improving patient outcomes, and democratizing access to spine knowledge.

Curing the 10,000 rare genetic diseases. We are uniting patient groups and populations to tackle the $1T rare disease market. We're going directly to patients, turning them into research scientists, and making them the center of focus.

The Quantum Biology DAO accelerates the quantum biology field through community building, open governance, scientific experimentation, research grants, and IP development. Together we will understand and manipulate biology at the quantum level.

PsyDAO fosters a vibrant community dedicated to conscious evolution through safe, accessible psychedelic experiences. United in purpose, we empower individuals and communities to explore transformative realms, igniting a future of shared awareness and growth.